Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill -- Ignore unavailable to you. Want to Upgrade?

To: Goose94 who wrote (42276)	5/3/2018 11:19:20 AM
From: Goose94	Respond to of 203627

Abattis Bioceuticals (ATT-Cse) halted

To: Goose94 who wrote (42276)	5/3/2018 12:18:46 PM
From: Goose94	Read Replies (1) \| Respond to of 203627

Abattis Bioceuticals (ATT-Cse) Commence Construction of Large-Scale Growing Facility on Gabriola Island May 3rd 2018 - NR Abattis Bioceuticals is pleased to announce the engagement (the “Engagement”) of Ocean Pacific Contractors Ltd. (“Ocean Pacific”) for construction of a purpose-built 26,000 square foot cannabis production and extraction facility (the “Facility”) on Gabriola Island, British Columbia. The Engagement follows completion of the Company’s recent acquisition of the remaining 10% interest in Gabriola Green Farms Inc. (“Gabriola”) from CannaNUMUS Blockchain Inc., as a result of which Gabriola is now a wholly-owned subsidiary of the Company. Through Gabriola, the Company is in the late stages of its application for a license to produce (the “LP”) under the Access to Cannabis for Medical Purposes Regulations. The Facility will be a state-of-the-art facility with proposed growing, extraction and propagation areas and a genetics lab. Under the terms of the Engagement, construction of the Facility will be completed in four stages, with estimated cost of $1.5m. On receipt of the LP, the Company will be licensed to produce and sell cannabis and cannabis derivatives. “The engagement of experienced construction contractors for our Gabriola facility crystallizes an important step in our path towards becoming a full service cannabis company," stated Rob Abenante, Abattis President and CEO. "Once we receive our license through Gabriola and complete construction of the Facility, we will have a large-scale platform from which to cultivate marijuana and produce and sell extracted cannabis products,” added Mr. Abenante. About Abattis Bioceuticals Corp. Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com. ON BEHALF OF THE BOARD OF ABATTIS BIOCEUTICALS CORP., "Rob Abenante" Robert Abenante, President & CEO For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.